Executive Summary
The global structural heart device market represents a technologically complex, Class II and Class III implantable medtech segment, distinct from coronary and peripheral intervention fields. While coronary therapies manage endovascular luminal narrowing due to atheromatous plaque, structural heart platforms remediate macro-architectural, hemodynamic, and congenital cardiac pathology across chambers, valves, septa, and adjacent great vessels. The addressable clinical landscape spans valvular calcific degeneration, high-volume functional regurgitation, cardioembolic reservoirs such as the left atrial appendage, congenital septal communications, and terminal biventricular heart failure.
The global structural heart device is valued at an estimated 17.1 to 18.1 billion USD in 2026, with a compound annual growth rate (CAGR) between 8.5% and 12.5% through 2031. This growth profile is supported by structural demographic shifts, clinical expansion into lower-risk and asymptomatic patient cohorts, and rapid technological iteration. Transcatheter Aortic Valve Replacement (TAVR) continues to provide the core revenue base. Simultaneously, capital allocation and clinical trial velocity are shifting aggressively toward Transcatheter Mitral and Tricuspid Therapies (TMTT), bioresorbable occlusion architectures, and short- to long-term mechanical circulatory support systems. Regulatory scrutiny, manufacturing hand-craftsmanship bottlenecks, and national reimbursement pricing pressures present operational hurdles. Even so, structural heart therapies maintain a high-growth trajectory within the global cardiovascular interventions sector.

Product Classification and Segment Analysis
● Valvular Heart Disease Devices
1. Transcatheter Heart Valves and Repair Systems
Catheter-directed therapies allow the deployment of biological valve replacements and mechanical reconstruction implants through transfemoral, transapical, or transseptal routes, avoiding median sternotomy and cardiopulmonary bypass.
Transcatheter Aortic Valve Replacement (TAVR/TAVI): TAVR anchors the modern structural heart market, moving from historically inoperable populations to low-risk and asymptomatic cohorts. Balloon-expandable platforms rely on Cobalt-Chromium (CoCr) or high-yield alloy frames (such as Edwards SAPIEN 3 Ultra RESILIA and Anteris DurAVR), offering precise annular deployment and radial strength. Self-expanding architectures utilize superelastic nitinol frames (such as Medtronic Evolut FX/FX+, Venus Medtech VenusA-Plus, Peijia Medical TaurusElite, MicroPort Vitaglow, and ScienTech ScienCrown). These preserve supra-annular hemodynamic output and enable intra-procedural recapture and repositioning.
Transcatheter Mitral and Tricuspid Therapies (TMTT): Mitral and tricuspid valve disease represent large, historically undertreated clinical populations.
Transcatheter Edge-to-Edge Repair (TEER) functions as the established first-line intervention for functional and degenerative regurgitation via targeted leaflet approximation. Market benchmarks include Abbott's MitraClip and TriClip, alongside Edwards Lifesciences' PASCAL system, Jenscare's JensClip, and Peijia's GeminiOne.
Transcatheter Valve Replacement targets anatomies unsuitable for edge-to-edge reconstruction. Tricuspid replacement has advanced rapidly following clinical validations, represented by the Edwards EVOQUE transfemoral system and Jenscare's LuX-Valve Plus (which utilizes non-radial anchoring to prevent conduction disturbance). Mitral replacement approaches require larger-profile delivery mechanisms to counteract high left ventricular closing pressures; these include Abbott's transapical Tendyne platform, HighLife's transseptal system, Edwards SAPIEN M3, Peijia Sutra Hemi-Valve, and Sinomed Accufit.
Transcatheter Pulmonary Valve Replacement (TPVR): TPVR treats right ventricular outflow tract (RVOT) dysfunction in adult and pediatric post-congenital repair settings. Medtronic's Melody and Harmony systems address both stenotic conduits and enlarged native outflow tracts. Venus Medtech's self-expanding VenusP-Valve and Taewoong Medical's PULSTA platform accommodate dilated anatomies without requiring pre-stenting.
2. Surgical Heart Valves and Repair Systems
Surgical intervention remains an essential pillar for complex multi-valve pathology, active infective endocarditis, and younger patient demographics requiring structural durability.
Surgical Tissue (Bioprosthetic) Valves: Fabricated from bovine pericardium or porcine aortic tissue, these valves utilize advanced chemical crosslinking and anti-calcification treatments. The Edwards Lifesciences RESILIA family (INSPIRIS RESILIA aortic, MITRIS RESILIA mitral, KONECT valved conduit) serves as an industry durability benchmark, relying on glycerol capping to prevent free aldehyde oxidation and allow dry-valve packaging. Sutureless or rapid-deployment valves, such as Corcym's Perceval platform, blend surgical leaflet durability with self-expanding nitinol frames to lower cross-clamp times.
Mechanical Heart Valves: Utilizing pyrolytic carbon bileaflet architectures and titanium housings, these devices provide wear-resistant durability for patients where lifetime mechanical wear outweighs the burden of lifelong warfarin anticoagulation. The Artivion On-X platform provides lower thrombogenicity profiles, allowing lower target International Normalized Ratios (INR 1.5 to 2.0). Abbott maintains market presence via its Masters and Regent Series, while TTK Healthcare serves cost-sensitive regional markets.
Surgical Annuloplasty and Tissue Reconstruction: Open-heart annuloplasty rings and bands (from Bairen Medical, Edwards, and Medtronic) stabilize native valve geometry during valve-sparing surgical interventions, supported by pericardial surgical reconstruction patches.
● Occluders and Closure Systems
1. Congenital Heart Disease (CHD) Occluders
Structural septal occluders correct intracardiac shunts across Atrial Septal Defects (ASD), Ventricular Septal Defects (VSD), and Patent Ductus Arteriosus (PDA). Metallic configurations traditionally combine double-umbrella nitinol wire meshes with internal polytetrafluoroethylene (PTFE) or polyethylene terephthalate (PET) blocking membranes (e.g., Lepu ScienTech MemoPart and Lifetech CeraFlex). The technology is shifting toward bioabsorbable polymer scaffolds, such as Lepu ScienTech’s MemoSorb series. These platforms utilize biodegradable poly-L-lactic acid (PLLA) matrices that degrade following progressive cellular endothelization, preventing late erosion and preserving access pathways across the interatrial septum.
2. Cardioembolic Stroke Prevention Occluders
Patent Foramen Ovale (PFO) Occluders: PFO closure is a standard therapeutic pathway for cryptogenic ischemic stroke in younger cohorts. Major systems include Abbott's Amplatzer PFO Occluder, Gore's CARDIOFORM, and Lepu ScienTech's bioresorbable MemoSorb PFO platform.
Left Atrial Appendage Occluders (LAAO): LAA closure mitigates cardioembolic stroke risks in non-valvular atrial fibrillation patients contra-indicated for long-term oral anticoagulants. Boston Scientific's WATCHMAN FLX / FLX Pro represents the leading plug-style occlusion mechanism, utilizing fluoropolymer coatings to accelerate healing. Abbott's Amplatzer Amulet uses a dual-seal (lobe and disc) mechanism for varied landing zones. Chinese regional designs, such as MicroPort’s AnchorMan and Lepu ScienTech’s MemoLefort, incorporate variable anchoring geometries for Asian anatomical variations.
3. Vascular Access and Structural Pathway Systems
Percutaneous structural operations rely on specialized high-caliber access and closure architectures. Large-bore femoral arteriotomy sites resulting from 14F to 24F delivery sheaths require active mechanical closure to prevent life-threatening hematomas and pseudoaneurysms. Primary solutions include Teleflex's collagen-plug-based MANTA device, Abbott's suture-based Perclose ProGlide / ProStyle, and specialized pre-embedded nitinol systems. Accessory pathways involve transseptal radiofrequency crossing needles, steerable large-bore guiding sheaths, and extra-stiff support guidewires.
● Ventricular Remodeling and Heart Failure Devices
1. Mechanical Circulatory Support (MCS) and Total Artificial Hearts (TAH)
End-stage heart failure progression creates clinical demand for mechanical devices that offload the ventricular myocardium or replace native biventricular pump function.
Total Artificial Hearts (TAH): Indicated for biventricular failure, complex congenital anomalies, or refractory allograft failure. Picard Medical’s SynCardia TAH remains the clinical standard for Bridge-to-Transplant (BTT), utilizing Segmented Polyurethane Solution (SPUS) housings and air-driven diaphragms providing up to 9.5 liters per minute of pulsatile flow. Alternative platforms include Scandinavian Real Heart’s dual-atrial pulsatile displacement pump, CARMAT's bioprosthetic-lined Aeson platform, and BiVACOR's maglev continuous-flow rotary system.
Left Ventricular Assist Devices (LVAD) and Percutaneous MCS: Long-term mechanical support relies on continuous-flow rotary blood pumps such as the Abbott HeartMate 3, which uses full magnetic levitation to reduce shear-induced hemolysis. Short-term support for cardiogenic shock relies on catheter-mounted micro-axial flow pumps, such as the Abiomed Impella platform, alongside emerging Chinese transcatheter percutaneous systems.
2. Structural Shunts, Neuromodulation, and Denervation
Interatrial Shunts: Engineered to manage elevated left atrial pressures in heart failure with preserved or reduced ejection fraction (HFpEF/HFrEF) by introducing calibrated left-to-right decompressing interatrial shunts.
Autonomic Neuromodulation and Cardiac Modulation: CVRx's Barostim delivers carotid baroreflex activation to regulate neurohormonal tone, while Cardiac Contractility Modulation (CCM) applies non-excitatory electrical signals during myocardial refractory phases to improve intracellular calcium handling.
Renal Denervation (RDN): Catheter-based sympathetic denervation systems (e.g., Medtronic Symplicity Spyral) target chronic neurogenic arterial hypertension, addressing a primary upstream driver of structural myocardial hypertrophy.

Downstream Indications and Clinical Demographics
The clinical utility of structural heart platforms is anchored to global cardiovascular epidemiology:
● Valvular Pathophysiology: Valvular diseases affect more than 28 million individuals globally. Aortic stenosis is common among aging populations, with severe symptomatic aortic stenosis carrying a 50% mortality rate at two years without valve replacement. Mitral regurgitation is the most common valve disorder worldwide, affecting a large functional population. Tricuspid regurgitation has transitioned from an historically neglected diagnosis to a target for catheter intervention, driven by high diagnostic rates via advanced echocardiography.
● The Global Heart Failure Burden: Heart failure impacts an estimated 64 million individuals globally, with five-year mortality for advanced stages exceeding 50%. This supports continued utilization of ventricular assist systems, interatrial venting devices, and biological pumps.
● Cardioembolic Thromboembolism: Atrial fibrillation drives up to 30% of global ischemic stroke events through thrombus formation within the left atrial appendage, establishing clinical indications for transcatheter exclusion systems. Concurrently, cryptogenic stroke populations maintain the procedural demand for PFO septal closure platforms.

Supply Chain and Value Chain Architecture
● Upstream: Material Science and Biologics Sourcing
Biologic Xenograft Tissue: Sourcing bovine pericardial membranes or porcine matrices requires secure, disease-free herds (primarily located across the United States, Australia, and New Zealand). Processing protocols demand strict clearance certifications to prevent viral transmission and eliminate Bovine Spongiform Encephalopathy (BSE) agents.
Specialty Superalloys: Nitinol (nickel-titanium) forms the metallurgical foundation for self-expanding valve cages and septal occluders due to its shape memory, superelasticity, and biocompatibility. Cobalt-Chromium alloys provide the radial yield strength and radio-opacity required for balloon-expandable stents, while pyrolytic carbon coatings on graphite substrates provide thrombo-resistant contact layers for mechanical implants.
Advanced Polymers: Fluoropolymers, including expanded polytetrafluoroethylene (ePTFE) and woven polyethylene terephthalate (PET), provide micro-porous coverage for tissue seal skirts, preventing paravalvular leak. Specialized synthetic polymers, such as segmented polyurethanes (SPUS) and biostable siloxane-polyurethanes (Elast-Eon), provide mechanical flexural life for artificial hearts and trileaflet polymeric valves.
● Midstream: Tissue Engineering and Cleanroom Hand-Assembly
Tissue Fixation and De-calcification: The proprietary core of biological valve manufacturing involves processing extracted pericardium through cross-linking agents. Advanced chemistries, such as the Edwards RESILIA process (glycerol capping) and the Anteris ADAPT tissue process (aldehyde detoxification), neutralize residual active glutaraldehyde molecules, mitigating post-implant calcium binding and eliminating liquid glutaraldehyde storage requirements.
Precision Assembly Operations: The mounting of biological tissue leaflets onto metallic frames remains largely unautomated. Highly trained cleanroom technicians manually stitch each leaflet to nitinol or CoCr frames under stereoscopic magnification within Class 7 / ISO cleanrooms. This reliance on manual assembly creates a structural capacity bottleneck across global manufacturing networks.
Quality Management and Regulatory Approvals: Facilities must adhere to ISO 13485 standards, United States FDA Class III Premarket Approval (PMA) regulations, and the European Union Medical Device Regulation (EU MDR 2017/745).
● Downstream: Clinical Field Engineering and Value Realization
Direct Proctoring Models: Unlike basic consumable medtech, the commercialization of structural heart platforms requires vendor-employed clinical specialists to proctor transcatheter valve and occluder deployments in hospital catheterization laboratories and hybrid operating rooms.
Consignment Inventory Structures: Structural heart delivery requires extensive consignment inventory management inside healthcare facilities. Hospitals maintain sizing matrices across all product categories without upfront capital outlays, invoicing the supplier only upon device deployment.
Health Economics and Outcomes Research (HEOR): Payer reimbursement approvals depend on real-world registry performance (e.g., STS/ACC TVT Registry data) demonstrating reductions in thirty-day all-cause mortality, shorter hospital stays, and lower 30-day readmission rates relative to open surgical standards.

Regional Market Dynamics
● North America
North America accounts for more than 50% of global structural heart market value. The United States market is characterized by high procedural adoption, high average selling prices (ASPs), and advanced hybrid OR infrastructure.
The US FDA Class III Premarket Approval (PMA) framework remains the global standard for clinical evidence, requiring randomized controlled trials with active long-term follow-up. Recent milestones include FDA Investigational Device Exemption (IDE) approval for Anteris Technologies' randomized PARADIGM trial evaluating its DurAVR platform, FDA approval for Abbott’s Tendyne TMVR system, and approvals for the Medtronic Evolut FX+ platform.
EBR Systems began commercializing its WiSE CRT pacing platform across US institutions following regulatory clearance. Reimbursement frameworks established by the Centers for Medicare and Medicaid Services (CMS) maintain broad coverage for TAVR across all clinical risk tiers, supported by dedicated Medicare Severity Diagnosis Related Groups (MS-DRGs).
● Europe
Europe represents the second-largest market, holding over 33% of global volume. Adoption rates for TAVR and TMTT are elevated across mature healthcare markets including Germany, France, Italy, and the UK.
Regulatory friction stemming from the transition to the European Medical Device Regulation (EU MDR 2017/745) continues to increase administrative and clinical follow-up overhead, prolonging review cycles and leading to selective portfolio rationalization among niche platforms. However, novel therapies continue to secure CE Mark clearance, including HighLife’s transseptal mitral replacement system in early 2026.
At the regional level, legislative modifications in Italy have capped historical hospital payback liabilities for device vendors (covering past public regional overspends from 2015 to 2018) to approximately 25% of originally claimed values, reducing financial balance sheet liabilities for operating entities.
● Asia-Pacific
The Asia-Pacific region is experiencing the fastest procedural volume growth, expanding at an estimated CAGR between 11.5% and 15.5%. Growth is anchored by healthcare modernization in China, established high-price access in Japan, and private tertiary hospital investments across India, Australia, and South Korea.
China is an active center for technological and policy evolution. The National Medical Products Administration (NMPA) operates an Innovation Medical Device Special Review Procedure ("Green Channel"), accelerating review for platforms that offer proprietary domestic intellectual property. Peijia Medical, MicroPort CardioFlow, Venus Medtech, Jenscare, and Balancemed have expanded commercial transcatheter pipelines through this mechanism.
Concurrently, Centralized Volume-Based Procurement (VBP) policies, directed regionally by entities such as the Fujian Provincial Healthcare Security Bureau, have targeted mature metallic septal occluders and basic vascular accessories, driving price reductions on older platforms.
This pricing compression has accelerated a clinical shift toward innovative, premium, non-VBP segments, notably fully bioabsorbable occluders (such as Lepu ScienTech’s MemoSorb line, which demonstrated over 30% volume expansion in 2025). Furthermore, standardized coding classifications issued by the National Healthcare Security Administration (NHSA) have streamlined inter-hospital billing pipelines, supporting procedural penetration into tertiary municipal centers.
Japan maintains high reimbursement rates and rigorous Pharmaceuticals and Medical Devices Agency (PMDA) regulatory standards, favoring established Western platforms. In India, multinational manufacturers compete with domestic producers like Meril Life Sciences and Sahajanand Medical Technologies (SMT), who deploy lower-cost balloon-expandable and self-expanding valve options. Taiwan, China maintains structured clinical adoption through national health insurance programs for high-risk transcatheter indications.
● Latin America
Latin America is an emerging market characterized by concentrated adoption in private healthcare networks across Brazil, Mexico, Colombia, and Argentina. Public healthcare reimbursement for complex structural interventions remains constrained, though private insurers and self-pay demographics support ongoing volume growth. Regional distribution commonly relies on hybrid models, utilizing third-party distribution partners supported by direct application specialists.
● Middle East and Africa (MEA)
The MEA region displays distinct structural market bifurcation. Gulf Cooperation Council (GCC) member nations (Saudi Arabia, the UAE, and Qatar) invest heavily in hybrid cardiac suites, acquiring advanced structural heart technologies at ASPs comparable to Western European benchmarks. Conversely, the public healthcare systems of Sub-Saharan Africa remain constrained by limited cardiac catheterization infrastructure and funding shortages, restricting advanced structural therapies to select private academic institutions.

Opportunities and Challenges
● Market Opportunities
Asymptomatic and Low-Risk Cohort Expansion: TAVR is moving beyond the boundaries of aged, high-risk populations. Clinical trial results, notably from the EARLY TAVR trial using Edwards SAPIEN 3, have confirmed the hemodynamic benefits of replacing stenotic valves prior to symptom manifestation, challenging watchful waiting strategies. This expands the eligible aortic stenosis addressable population.
Indication Expansion into Pure Aortic Regurgitation: Transcatheter deployment has traditionally targeted calcified aortic stenosis due to the radial friction anchoring required by earlier-generation stents. The introduction of dedicated clamping and positioning clips, exemplified by the JenaValve Trilogy architecture (licensed domestically as Peijia’s TaurusTrio), establishes a viable therapeutic approach for pure non-calcified aortic regurgitation, unlocking a historically surgical-only cohort.
Scale Potential of the TMTT Landscape: Because the combined incidence of severe functional mitral and tricuspid regurgitation exceeds that of calcific aortic stenosis, TMTT presents a larger potential market. As edge-to-edge platforms (MitraClip, PASCAL, JensClip) are augmented by transfemoral replacement systems (such as EVOQUE for the tricuspid valve and Tendyne or HighLife for the mitral position), procedural volumes are expected to expand across heart failure networks.
Material Evolution to Bioresorbable Scaffolding and Dry Tissues: Metallic occluders leave permanent foreign materials within the heart, preventing future transseptal crossing and risking continuous low-level nickel elution. Bioresorbable matrices address these long-term concerns, driving replacement cycles. Simultaneously, the adoption of glutaraldehyde-free, dry-stored pericardial leaflets reduces structural valve degeneration (SVD) and simplifies hospital supply chain logistics by removing the need for saline rinsing cycles prior to implantation.
Total Artificial Heart and Minimally Invasive MCS Adoption: With the donor heart supply structurally capped below 6,000 procedures globally each year, end-stage heart failure populations require alternative durable options. Advancements in continuous-flow pulsatile artificial hearts and smaller percutaneous unloading pumps create opportunities to manage advanced heart failure.
● Industry Challenges and Structural Inhibitors
Pricing Erosion and Public Tender Mechanisms: State-run tender mechanisms, including national and provincial procurement frameworks in China, alongside cost-containment programs across European single-payer health networks, are driving down average selling prices on mature devices. Manufacturers face gross margin compression on legacy product lines, necessitating manufacturing efficiencies or transitions toward proprietary, non-tendered technologies.
R&D Capital Demands and Pipeline Pruning: Structural heart innovation requires sustained high research and development capital, frequently demanding 15% to 20% of topline revenue. Complex multi-center clinical trials carry high clinical and financial risk profiles. Sub-scale or trailing programs face sudden cancellation, illustrated by Boston Scientific's operational decision to discontinue its ACURATE TAVR platform globally, resulting in approximately $87 million in restructuring and write-off charges.
Proctoring Overhead and Operator Learning Curves: Unlike coronary stenting, transcatheter mitral and tricuspid interventions require real-time 3D transesophageal echocardiography (TEE) navigation, complex multi-planar intracardiac guidance, and direct supplier proctoring. The time required to train structural heart heart teams restricts procedural operations to high-volume tertiary hospitals, limiting access in community and rural healthcare systems.

Company Profiles
1. Multi-Segment Diversified Leaders
● Abbott Laboratories
Abbott maintains an expansive structural heart portfolio, holding a strong position in transcatheter edge-to-edge repair through the MitraClip and TriClip product lines. The company has expanded its transcatheter footprint with the Tendyne transapical TMVR system, while marketing the Navitor TAVI platform (featuring active sealing cuffs) for aortic interventions. Abbott's occlusion business centers on the Amplatzer portfolio, featuring the Amplatzer Amulet for left atrial appendage occlusion, alongside dedicated congenital defect devices like the Amplatzer Piccolo, the first transcatheter system approved for low-weight neonates. The surgical business is anchored by the Regent and Masters series pyrolytic mechanical valves.
● Edwards Lifesciences Corporation
Edwards Lifesciences remains a dedicated pure-play leader in structural heart innovation, allocating approximately 18% of revenue to internal R&D. Its operational moat in TAVR is supported by the balloon-expandable SAPIEN 3 Ultra platform, which incorporates RESILIA anti-calcification tissue to support dry-packaging and structural durability. Within TMTT, Edwards commercializes the PASCAL Precision repair system and the EVOQUE system, the first commercially approved transcatheter tricuspid replacement system in major markets. Its surgical business is anchored by the INSPIRIS RESILIA aortic and MITRIS RESILIA mitral bioprosthetic valves.
● Medtronic plc
Medtronic holds a major share of the global self-expanding TAVR market through its supra-annular CoreValve Evolut platform (incorporating the Evolut FX and Evolut FX+ iterations), which provides low post-procedural transvalvular gradients across small aortic annuli. In the transcatheter pulmonary space, Medtronic provides the Harmony and Melody TPV systems, addressing native and conduit RVOT anatomies. Its transcatheter mitral pipeline features the Intrepid TMVR system, which is undergoing clinical evaluation for both transfemoral-transseptal and transapical access. The company's surgical offering includes the Hancock II and Mosaic tissue valves, supplemented by the Symplicity Spyral renal denervation system for upstream hypertension management.
● Boston Scientific Corporation
Boston Scientific’s primary structural heart pillar is the WATCHMAN and WATCHMAN FLX / FLX Pro Left Atrial Appendage Closure (LAAC) franchise, which functions as an alternative to long-term oral anticoagulation in non-valvular AF. Following the strategic portfolio discontinuation of the ACURATE neo2 / Prime TAVR program to cut operational overhead, the company has redirected capital toward its LAAC portfolio, structural imaging accessories, and large-scale acquisitions, including its strategic bid for Penumbra to build out vascular access and thrombectomy workflows.
2. Congenital Occlusion and Structural Pathway Specialists
● W. L. Gore and Associates, Inc. (Gore Medical)
Gore leverages its proprietary fluoropolymer and biomaterial platforms to manufacture low-profile structural heart closure devices. Its core portfolio includes the GORE CARDIOFORM Septal Occluder and CARDIOFORM ASD Occluder, which integrate platinum-filled nitinol frames with microporous expanded polytetrafluoroethylene (ePTFE) membranes. This design promotes rapid tissue endothelialization, lowers thrombogenicity, and reduces mechanical profile strain on cardiac septa relative to traditional thick wire hubs.
● Lifetech Scientific Corporation
Based in Shenzhen, Lifetech specializes in structural heart occluders and minimally invasive peripheral devices. Its congenital line includes the Cera and CeraFlex septal platforms, which use titanium nitride (TiN) nano-coatings to prevent nickel ion leaching and lower surface thrombogenicity. In stroke prevention, Lifetech markets the LAmbre LAA Closure System, designed with variable anchor structures to stabilize implants across diverse atrial anatomies. The company's transcatheter pipeline includes the C-Valve TAVR and the Fit-Trans pulmonary valve.
3. Surgical Bioprosthetic and Tissue Engineering Pioneers
● Artivion, Inc.
Headquartered in the United States, Artivion specializes in surgical cardiac and aortic repair. Its product line centers on the On-X Prosthetic Heart Valve, a bileaflet pyrolytic carbon mechanical valve cleared by the US FDA for reduced oral anticoagulation management (target INR 1.5 to 2.0). Artivion also processes decellularized human pulmonary and aortic allografts (SynerGraft), alongside PhotoFix decellularized bovine pericardial reconstructive patches and the AMDS hybrid aortic graft for acute DeBakey Type I dissections.
● Corcym S.r.l.
Formed through the carve-out of LivaNova’s heart valve division, Corcym is a European surgical device manufacturer. Its core product is the Perceval and Perceval Plus sutureless bioprosthetic aortic valve, which uses a self-expanding nitinol frame to eliminate surgical suturing, reducing cardiopulmonary bypass times. The company also produces the Carbomedics mechanical valve line, Crown PRT stented tissue valves, and Memo 4D annuloplasty rings.
● Beijing Balance Medical Technology Co., Ltd. (Balancemed)
Listed on the Shanghai STAR Market, Balancemed specializes in animal-derived regenerative biomaterials and decellularized tissue engineering. The company developed the first domestically approved bovine pericardial bioprosthesis in China and supplies porcine tissue valves, surgical annuloplasty rings, and pulmonary valved conduits. Balancemed is expanding into transcatheter therapies with the Renatus TAVR platform and the Renato valve-in-valve system.
● KingstronBio Co., Ltd.
KingstronBio develops bioprosthetic tissue valves and minimally invasive transcatheter implants using its Micro-Ex cross-linking technology. Its surgical lines include the X-Link bovine pericardial valve and dry-tissue, non-glutaraldehyde pericardial patches. Its transcatheter pipeline includes the Prostyle A TAVR platform and the Prostyle M mitral replacement system.
4. The Rest of Companies Covered: MicroPort Scientific Corporation, Venus Medtech (Hangzhou) Inc., Peijia Medical Limited, ScienTech Medical, Jenscare Scientific Co., Ltd., Shanghai NewMed Medical Co., Ltd., Jiangsu Trulive Medtech Co., Ltd., Lepu Medical Technology (Beijing) Co., Ltd., Sino Medical Sciences Technology Inc. (SINOMED), Meril Life Sciences Pvt. Ltd., Sahajanand Medical Technologies Ltd. (SMT), Relisys Medical Devices Limited, Biosensors International Group, Taewoong Medical Co., Ltd., Anteris Technologies Ltd.